SLC6A3 and Parkinson disease: Moreover, it has been reported that PD-RBD patients exhibit a more rapid decrease in DAT binding, and the distinct pattern of striatal DAT binding may contribute to the more malignant subtype—PD-RBD (Cao et al., 2020).